Literature DB >> 18644036

Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia.

J Schoenen1, N De Klippel, S Giurgea, L Herroelen, J Jacquy, P Louis, G Monseu, M Vandenheede.   

Abstract

Early treatment and combining a triptan with a non-steroidal anti-inflammatory drug (NSAID) are thought to improve outcome during migraine attacks, possibly by counteracting the negative influence of cutaneous allodynia. The aim of this multicentre, double-blind pilot study was to evaluate the prevalence of brush allodynia and its relative influence on the efficacy of a triptan-NSAID combination compared with headache intensity at the time of treatment. In a randomized, cross-over design, 112 migraineurs treated two moderate or severe attacks with almotriptan 12.5 mg combined with either aceclofenac 100 mg or placebo. Patients used a 2-cm brush to assess cutaneous allodynia. Allodynia was reported in 34.4% of attacks. The almotriptan-aceclofenac combination was numerically superior to triptan-placebo on 2-24-h sustained pain-free (P = 0.07), 2-h pain-free (P = 0.07) and headache recurrence (P = 0.05) rates, but not on 1-h headache relief. Allodynia numerically reduced treatment success overall, but this effect was not significant for the primary outcome measures. Headache intensity had a significant negative influence on 1-h relief in both attacks (P = 0.0001 and 0.0008, chi(2)) and on 2-24-h sustained pain-free rates in triptan-placebo-treated attacks (P = 0.013). Multivariate logistic regression analysis confirmed that headache intensity at treatment intake, rather than allodynia, significantly influenced most outcome measures, predominantly so in attacks treated with almotriptan and aceclofenac. In the latter, severe compared with moderate headache intensity reduced the likelihood of achieving the primary efficacy end-points [odds ratios (OR) 0.12 and 0.33], whereas allodynia was not a significant explanatory variable (OR 0.76 and 0.65). The results apply to the protocol used here and need to be confirmed in larger studies using quantitative sensory testing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18644036     DOI: 10.1111/j.1468-2982.2008.01654.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  10 in total

Review 1.  Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?

Authors:  Andreas Straube; Bernhard Aicher; Bernd L Fiebich; Gunther Haag
Journal:  BMC Neurol       Date:  2011-03-31       Impact factor: 2.474

2.  MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments.

Authors:  Stewart J Tepper; Shashidhar H Kori; Peter J Goadsby; Paul K Winner; Min H Wang; Stephen D Silberstein; F Michael Cutrer
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

Review 3.  Treatment of pediatric migraine in the emergency room.

Authors:  Amy A Gelfand; Peter J Goadsby
Journal:  Pediatr Neurol       Date:  2012-10       Impact factor: 3.372

4.  Allodynia as a complication of migraine: background and management.

Authors:  William B Young
Journal:  Curr Treat Options Neurol       Date:  2009-01       Impact factor: 3.598

Review 5.  Are the current IHS guidelines for migraine drug trials being followed?

Authors:  Anders Hougaard; Peer Tfelt-Hansen
Journal:  J Headache Pain       Date:  2010-10-08       Impact factor: 7.277

6.  Two TRPV1 receptor antagonists are effective in two different experimental models of migraine.

Authors:  Jannis E Meents; Jan Hoffmann; Sandra R Chaplan; Lars Neeb; Sigrid Schuh-Hofer; Alan Wickenden; Uwe Reuter
Journal:  J Headache Pain       Date:  2015-06-24       Impact factor: 7.277

7.  Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura.

Authors:  Gianni Allais; Vincenzo Tullo; Pietro Cortelli; Piero Barbanti; Fabio Valguarnera; Giuliano Sette; Florindo D'Onofrio; Marcella Curone; Dario Zava; Deborha Pezzola; Giorgio Reggiardo; Stefano Omboni; Fabio Frediani; Gennaro Bussone; Chiara Benedetto
Journal:  Neurol Sci       Date:  2014-05       Impact factor: 3.307

8.  Current migraine management - patient acceptability and future approaches.

Authors:  Arnaud Fumal; Jean Schoenen
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

Review 9.  NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data.

Authors:  Arpad Pardutz; Jean Schoenen
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-17

10.  Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity.

Authors:  Simon Akerman; Nazia Karsan; Pyari Bose; Jan R Hoffmann; Philip R Holland; Marcela Romero-Reyes; Peter J Goadsby
Journal:  Brain       Date:  2019-01-01       Impact factor: 13.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.